{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:51Z","timestamp":1761178611190,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.canrad.2023.06.022","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T12:54:55Z","timestamp":1691067295000},"page":"568-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioth\u00e9rapie st\u00e9r\u00e9otaxique des carcinomes r\u00e9naux primitifs"],"prefix":"10.1016","volume":"27","author":[{"given":"L.","family":"Abancourt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Le Gu\u00e9velou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Taillez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Mirabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9.","family":"Lartigau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-7309","authenticated-orcid":false,"given":"D.","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.06.022_bib0135","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.canrad.2023.06.022_bib0140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(22)01059-5","article-title":"The multispeciality approach to the management of localised kidney cancer","volume":"400","author":"Stewart","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.06.022_bib0145","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/S0360-3016(03)01136-2","article-title":"Stereotactic extracranial radiosurgery for renal cell carcinoma","volume":"57","author":"Qian","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.06.022_bib0150","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0155","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK): pooled analysis of SABR for primary RCC","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2023.06.022_bib0160","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for \u2265T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.06.022_bib0165","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon.16.2","article-title":"Consensus statement from the International radiosurgery oncology consortium for kidney for primary renal cell carcinoma","volume":"12","author":"Siva","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0170","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1148\/rg.2021200202","article-title":"Role of imaging in renal cell carcinoma: a multidisciplinary perspective","volume":"41","author":"Abou Elkassem","year":"2021","journal-title":"RadioGraphics"},{"key":"10.1016\/j.canrad.2023.06.022_bib0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0180","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2013.06.218","article-title":"A phase 1\u00a0dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma","volume":"87","author":"McBride","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.06.022_bib0185","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.prro.2022.06.012","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell cancer: 24-month results of the RSR1\u00a0phase 1\u00a0dose escalation study","volume":"13","author":"Lapierre","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0190","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canrad.2021.11.001","article-title":"Organs at risk radiation dose constraints","volume":"26","author":"No\u00ebl","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.06.022_bib0200","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0205","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clon.2022.06.007","article-title":"Stereotactic body radiotherapy for renal cell carcinoma: oncological and renal function outcomes","volume":"35","author":"Glicksman","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2023.06.022_bib0210","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clon.2021.03.002","article-title":"Patient-reported quality of life following stereotactic body radiation therapy for primary kidney cancer\u00a0\u2013\u00a0results from a prospective cohort study","volume":"33","author":"Swaminath","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2023.06.022_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2023.02.016","article-title":"Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer","author":"Hannan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022\u00a0update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0225","unstructured":"Urofrance | Recommandations du comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie \u2013\u00a0actualisation 2022-2024\u00a0: prise en charge du cancer du rein\u00a0\u2013 Urofrance n.d. https:\/\/www.urofrance.org\/recommandation\/recommandations-du-comite-de-cancerologie-de-lassociation-francaise-durologie-actualisation-2022-2024-prise-en-charge-du-cancer-du-rein\/. (accessed May 18, 2023)."},{"key":"10.1016\/j.canrad.2023.06.022_bib0230","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/JU.0000000000000111","article-title":"Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK","volume":"201","author":"Correa","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmp.2021.07.020","article-title":"Reducing the impact on renal function of kidney SABR through management of respiratory motion","volume":"89","author":"Gaudreault","year":"2021","journal-title":"Phys Med"},{"key":"10.1016\/j.canrad.2023.06.022_bib0240","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/cancers12102763","article-title":"The role of daily adaptive stereotactic mr-guided radiotherapy for renal cell cancer","volume":"12","author":"Tetar","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2023.06.022_bib0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canrad.2023.06.022_bib0250","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0255","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2023.06.022_bib0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canrad.2021.11.011","article-title":"Specificities of clinical research in radiotherapy","volume":"26","author":"Hennequin","year":"2022","journal-title":"Cancer Radiother"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:39:03Z","timestamp":1761136743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":26,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1278321823001361"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.022","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioth\u00e9rapie st\u00e9r\u00e9otaxique des carcinomes r\u00e9naux primitifs","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}